Comparative Pharmacology
Head-to-head clinical analysis: BACI RX versus LUMI SPORYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACI RX versus LUMI SPORYN.
BACI-RX vs LUMI-SPORYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
LUMI-SPORYN is a synthetic antimicrobial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, leading to impaired cross-linking of peptidoglycan and osmotic lysis. It also exhibits concentration-dependent bactericidal activity.
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
1000 mg IV every 8 hours over 1 hour for adults with normal renal function.
None Documented
None Documented
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 mL/min.
6-8 hours; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Renal 70-80% unchanged, biliary/fecal 20-30%
Category C
Category C
Topical Antibiotic
Topical Antibiotic